Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping-Reference-Cited by-同舟云学术

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Published:2016-08 Issue:8 Volume:11 Page:1242-1245
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Heist Rebecca S.,Sequist Lecia V.,Borger Darrell,Gainor Justin F.,Arellano Ronald S.,Le Long P.,Dias-Santagata Dora,Clark Jeffrey W.,Engelman Jeffrey A.,Shaw Alice T.,Iafrate A. John

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. Somatic mutations lead to an oncogenic deletion of met in lung cancer;Kong-Beltran;Cancer Res,2006

2. Comprehensive molecular profiling of lung adenocarcinoma;Nature,2014

3. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping;Paik;Cancer Discov,2015

4. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors;Frampton;Cancer Disov,2015

5. MET exon 14 skipping in non-small cell lung cancer;Heist;Oncologist,2016

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation;Lung Cancer: Targets and Therapy;2024-08

2. Recording and classifying MET receptor mutations in cancers;eLife;2024-04-23

3. Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer;Cancer Letters;2024-04

4. Oncogenic alterations in advanced NSCLC: a molecular super-highway;Biomarker Research;2024-02-12

5. Screening Ultra-Large Encoded Compound Libraries Leads to Novel Protein–Ligand Interactions and High Selectivity;Journal of Medicinal Chemistry;2024-01-10